A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

A Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Pramlintide Acetate When Administered by Subcutaneous Infusion in a Basal-Bolus Manner as an Adjunct to Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes

This research project will investigate the effects of pramlintide (Symlin) given by continuous subcutaneous (under the skin) infusion throughout the day and night, along with meal doses similar to those injected during conventional pramlintide (Symlin) treatment, delivered using a second insulin pump, in subjects with inadequately controlled type I diabetes mellitus who are already using insulin pump therapy. Study participants will wear two pumps for a four month period, taking insulin in their usual manner and pramlintide (Symlin) in a similar basal/bolus fashion. Continuous glucose monitors will be worn on three occasions during the study to assess blood glucose responses to continuous pramlintide (Symlin) treatment.

Study Overview

• Status: Completed
• Conditions: IDDM
• Intervention / Treatment: Drug: Continuous Pramlintide infusion

Detailed Description

DESCRIPTION OF STUDY:

To participate in the study, you must have Type I diabetes mellitus and be taking insulin using an insulin pump, and have a hemoglobin A1c level between 7.0% and 10.0%. You will not be permitted to participate in the study if you have taken pramlintide (Symlin) during the previous three months. The study will consist of seven visits to the Study Center over a four-month period. Subjects will undergo meal tolerance testing at beginning and end of study period. Continuous blood glucose monitoring will be performed on three occasions during the study.

Pramlintide will be begun at a single basal rate of 1.5 units/hr. Bolus therapy will be begun thereafter per standard manufacturer protocol. Subjects will be monitored for three months on basal-bolus pramlintide therapy.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Tennessee
    • Chattanooga, Tennessee, United States, 37403
      • University Diabetes & Endocrine Consultants

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Type 1 diabetes of at least one year duration;
2. Treated with CSII therapy for at least 6 months;
3. Age 18 to 70 years, inclusive;
4. A1C >7.0 and ≤10% as screening;
5. BMI ≤35 kg/m2;
6. Stable insulin dose (±10%) for at least 3 months prior to screening;
7. If female, has a negative urine pregnancy test at screening;
8. If female and of childbearing potential, practicing and willing to continue to using appropriate contraception to ensure that pregnancy does not occur during the study;
9. Able to understand and sign the required study documents and comply with the protocol requirements

Exclusion Criteria:

1. Is poorly compliant with the currently prescribed insulin regimen, as determined by the investigator;
2. Has any significant medical condition, laboratory findings, or medical history that may affect successful completion of the study and/or personal well-being;
3. If female and if of childbearing potential, is pregnant, lactating, or planning to become pregnant;
4. Has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months;
5. Has a history of hypoglycemia unawareness;
6. Has a confirmed diagnosis of gastroparesis;
7. Requires the use of drugs that stimulate gastrointestinal motility;
8. Is receiving medications known to interfere with glycemic control (i.e. glucocorticoids);
9. Has been treated with any oral antidiabetic agent or exenatide within 3 months of screening visit;
10. Has been treated with pramlintide within 3 months of screening visit;
11. Has received an investigational drug within 3 month of screening visit;
12. Is currently participating in a clinical trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: A; Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion	Drug: Continuous Pramlintide infusion; pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses; Other Names: pramlintide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Fasting and postprandial pramlintide pharmacokinetics	Four months

Secondary Outcome Measures

Outcome Measure	Time Frame
Hemoglobin A1c, body weight, blood glucose variability, patient satisfaction	four months
Hemoglobin A1c	16 weeks

Collaborators and Investigators

• Sponsor: University Diabetes & Endocrine Consultants
• Collaborators: Amylin Pharmaceuticals, LLC.
• Investigators: Principal Investigator: David M Huffman, MD, University Diabetes & Endocrine Consultants

Publications and helpful links

General Publications

• Huffman DM, McLean GW, Seagrove MA. Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. Endocr Pract. 2009 Nov-Dec;15(7):689-95. doi: 10.4158/EP09044.ORR1.

Study record dates

Study Major Dates

• Study Start: July 1, 2007
• Primary Completion (Actual): January 1, 2008
• Study Completion (Actual): January 1, 2008

Study Registration Dates

• First Submitted: July 16, 2007
• First Submitted That Met QC Criteria: July 16, 2007
• First Posted (Estimate): July 17, 2007

Study Record Updates

• Last Update Posted (Estimate): January 16, 2013
• Last Update Submitted That Met QC Criteria: January 15, 2013
• Last Verified: January 1, 2013

More Information

Terms related to this study

• Keywords: diabetes; insulin; IDDM; pramlintide
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Appetite Depressants; Anti-Obesity Agents; Amylin Receptor Agonists; Pramlintide; Islet Amyloid Polypeptide
• Other Study ID Numbers: Pramlintide Infusion in IDDM